Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...

The R.I. Life Science Hub is leading development of our state’s first life science incubator, and is already generating a great return on our investment, writes House Speaker K. Joseph Shekarchi ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around $130, and later that year it climbed as high as $449, as investors ...

Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...

An ambitious start-up embodies new optimism that artificial intelligence can turbocharge scientific discovery. An ambitious start-up embodies new optimism that artificial intelligence can ...

Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of infringing were invalid. The companies have secured a victory in a round in their ...

Moderna has been hit by massive insider selling over the last couple of years. The stock has a 52-week high of over $170 while Moderna entered 2020 trading below $20, making insiders more likely ...